

May 23, 2013, 4:13 a.m. EDT

BTG to buy EKOS for \$220 mln

By Deutsche Bank AG

LONDON--Healthcare company BTG PLC Thursday announced that it has entered into an agreement to buy EKOS Corporation on a debt free cash free basis for an initial cash consideration of \$180 million (120 million pounds) and up to \$40 million (GBP27 million) in future milestone payments.

MAIN FACTS:

-EKOS is headquartered near Seattle, Washington, and manufactures interventional products for the treatment of severe blood clots.

-Attractive financial impact with an estimated ROI in line with BTG's target for this type of acquisition of 15% to 20% in year five.

-As at March 31, BTG had cash and cash equivalents of GBP158.7 million.

-Acquisition will be funded in part from BTG existing cash resources, with the balance being funded by part of the net proceeds of a placing of up to 32.8 million new ordinary shares.

-Closing of the EKOS Acquisition is conditional on Hart-Scott-Rodino (HSR) approval in the U.S..

-BTG was advised by Stephenson Harwood and Morgan Lewis; N.M. Rothschild provided general corporate advice to BTG.

-Shares on Wednesday closed at 338 pence.

Copyright © 2013 MarketWatch, Inc. All rights reserved.